{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:32:44Z","timestamp":1793298764788,"version":"4.5.0"},"reference-count":143,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","award":["07\/SRC\/B1154"],"award-info":[{"award-number":["07\/SRC\/B1154"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.drudis.2014.09.011","type":"journal-article","created":{"date-parts":[[2014,9,26]],"date-time":"2014-09-26T18:12:09Z","timestamp":1411755129000},"page":"50-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Delivering a disease-modifying treatment for Huntington's disease"],"prefix":"10.1016","volume":"20","author":[{"given":"Bruno M.D.C.","family":"Godinho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitriona M.","family":"O\u2019Driscoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Cryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2014.09.011_bib0005","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1474-4422(10)70287-8","article-title":"Accurate prevalence and uptake of testing for Huntington's disease","volume":"9","author":"Morrison","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.drudis.2014.09.011_bib0010","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/mds.25075","article-title":"The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis","volume":"27","author":"Pringsheim","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.drudis.2014.09.011_bib0015","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1073\/pnas.0308679101","article-title":"Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset","volume":"101","author":"Wexler","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2014.09.011_bib0020","series-title":"Huntington's Disease","author":"Bates","year":"2002"},{"key":"10.1016\/j.drudis.2014.09.011_bib0025","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington's disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.drudis.2014.09.011_bib0030","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","author":"MacDonald","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2014.09.011_bib0035","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1042\/BJ20071619","article-title":"Huntington's disease: from pathology and genetics to potential therapies","volume":"412","author":"Imarisio","year":"2008","journal-title":"Biochem. J."},{"key":"10.1016\/j.drudis.2014.09.011_bib0040","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/ana.10094","article-title":"Environmental enrichment slows disease progression in R6\/2 Huntington's disease mice","volume":"51","author":"Hockly","year":"2002","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.drudis.2014.09.011_bib0045","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1523\/JNEUROSCI.1658-03.2004","article-title":"Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism","volume":"24","author":"Spires","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.drudis.2014.09.011_bib0050","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1172\/JCI45130","article-title":"Oligonucleotide therapeutic approaches for Huntington disease","volume":"121","author":"Sah","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2014.09.011_bib0055","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2174\/1389201043376689","article-title":"Anti-genes: siRNA, ribozymes and antisense","volume":"5","author":"Scanlon","year":"2004","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.drudis.2014.09.011_bib0060","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1574-6976.1999.tb00399.x","article-title":"Ribozymes: the characteristics and properties of catalytic RNAs","volume":"23","author":"Tanner","year":"1999","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.drudis.2014.09.011_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1432-1033.1997.t01-3-00001.x","article-title":"The structure, function and application of the hammerhead ribozyme","volume":"245","author":"Birikh","year":"1997","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.drudis.2014.09.011_bib0070","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.cell.2009.02.002","article-title":"Crawling out of the RNA world","volume":"136","author":"Cech","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2014.09.011_bib0075","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.nbd.2007.11.003","article-title":"Unexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in vivo","volume":"29","author":"Denovan-Wright","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.drudis.2014.09.011_bib0080","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ymthe.2005.05.006","article-title":"Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6\/1 Huntington's disease transgenic mice","volume":"12","author":"Rodriguez-Lebron","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drudis.2014.09.011_bib0085","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.bbrc.2006.01.057","article-title":"Down-regulation of \u03b1-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model","volume":"341","author":"Hayashita-Kinoh","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drudis.2014.09.011_bib0090","article-title":"Silencing of amyloid precursor protein expression using a new engineered delta ribozyme","volume":"2012","author":"Ben Aissa","year":"2012","journal-title":"Int. J. Alzheimer's Dis."},{"key":"10.1016\/j.drudis.2014.09.011_bib0095","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/ng0498-378","article-title":"Ribozyme-mediated trans-splicing of a trinucleotide repeat","volume":"18","author":"Phylactou","year":"1998","journal-title":"Nat. Genet."},{"key":"10.1016\/j.drudis.2014.09.011_bib0100","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.chembiol.2009.01.008","article-title":"Biologically inspired synthetic enzymes made from DNA","volume":"16","author":"Schlosser","year":"2009","journal-title":"Chem. Biol."},{"key":"10.1016\/j.drudis.2014.09.011_bib0105","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/1531-8249(199909)46:3<366::AID-ANA12>3.0.CO;2-D","article-title":"Sequence-specific cleavage of Huntingtin mRNA by catalytic DNA","volume":"46","author":"Yen","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.drudis.2014.09.011_bib0110","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.molmed.2012.09.001","article-title":"Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases","volume":"18","author":"Southwell","year":"2012","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.drudis.2014.09.011_bib0115","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1440-1681.2006.04403.x","article-title":"Antisense oligonucleotides: from design to therapeutic application","volume":"33","author":"Chan","year":"2006","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.drudis.2014.09.011_bib0120","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1172\/JCI25424","article-title":"Antisense oligonucleotide therapy for neurodegenerative disease","volume":"116","author":"Smith","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2014.09.011_bib0125","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0006-291X(02)02013-2","article-title":"Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo","volume":"296","author":"Bertrand","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drudis.2014.09.011_bib0130","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1006\/exnr.1996.6400","article-title":"Antisense gene therapy for neurodegenerative disease?","volume":"144","author":"Haque","year":"1997","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.drudis.2014.09.011_bib0135","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1021\/bi101208k","article-title":"Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat","volume":"49","author":"Gagnon","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2014.09.011_bib0140","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1749-6632.2009.04975.x","article-title":"Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA","volume":"1175","author":"Hu","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.drudis.2014.09.011_bib0145","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/mt.2011.201","article-title":"Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene\/allele-specific silencing of mutant huntingtin","volume":"19","author":"Carroll","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drudis.2014.09.011_bib0150","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.drudis.2014.09.011_bib0155","doi-asserted-by":"crossref","first-page":"9634","DOI":"10.1093\/nar\/gkt725","article-title":"Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS","volume":"41","author":"Ostergaard","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.drudis.2014.09.011_bib0160","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","article-title":"An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study","volume":"12","author":"Miller","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.drudis.2014.09.011_bib0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/108729003764097296","article-title":"Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells","volume":"13","author":"Miyagishi","year":"2003","journal-title":"Antisense Nucleic Acid Drug. Dev."},{"key":"10.1016\/j.drudis.2014.09.011_bib0170","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2307\/3869076","article-title":"Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans","volume":"2","author":"Napoli","year":"1990","journal-title":"Plant Cell Online"},{"key":"10.1016\/j.drudis.2014.09.011_bib0175","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2014.09.011_bib0180","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/35078107","article-title":"Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells","volume":"411","author":"Elbashir","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2014.09.011_bib0185","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrm2347","article-title":"Small non-coding RNAs in animal development","volume":"9","author":"Stefani","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.drudis.2014.09.011_bib0190","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nrg1379","article-title":"MicroRNAs: small RNAs with a big role in gene regulation","volume":"5","author":"He","year":"2004","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.drudis.2014.09.011_bib0195","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/MMBR.67.4.657-685.2003","article-title":"RNA interference: biology, mechanism, and applications","volume":"67","author":"Agrawal","year":"2003","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.drudis.2014.09.011_bib0200","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0092-8674(00)80620-0","article-title":"RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals","volume":"101","author":"Zamore","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2014.09.011_bib0205","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0092-8674(02)00908-X","article-title":"Single-stranded antisense siRNAs guide target RNA cleavage in RNAi","volume":"110","author":"Martinez","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2014.09.011_bib0210","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1007\/s11095-011-0608-1","article-title":"Subcellular fate and off-target effects of siRNA, shRNA, and miRNA","volume":"28","author":"Singh","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.drudis.2014.09.011_bib0215","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.addr.2007.03.008","article-title":"shRNA and siRNA delivery to the brain","volume":"59","author":"Pardridge","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.drudis.2014.09.011_bib0220","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.pharmthera.2005.08.006","article-title":"Interfering with the brain: use of RNA interference for understanding the pathophysiology of psychiatric and neurological disorders","volume":"109","author":"Thakker","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2014.09.011_bib0225","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/sj.mp.4001687","article-title":"siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain","volume":"10","author":"Thakker","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.drudis.2014.09.011_bib0230","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/978-1-59745-191-8_18","article-title":"Transgenic RNA interference in mice","volume":"442","author":"Zhang","year":"2008","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.drudis.2014.09.011_bib0235","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1152\/physiol.00002.2007","article-title":"Transgenic RNA interference in mice","volume":"22","author":"Gao","year":"2007","journal-title":"Physiology"},{"key":"10.1016\/j.drudis.2014.09.011_bib0240","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/978-1-59745-471-1_6","article-title":"Generation of shRNA transgenic mice","volume":"530","author":"Hitz","year":"2009","journal-title":"Gene Knockout Protoc."},{"key":"10.1016\/j.drudis.2014.09.011_bib0245","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.addr.2007.03.005","article-title":"RNAi therapeutics: principles, prospects and challenges","volume":"59","author":"Aagaard","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.drudis.2014.09.011_bib0250","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrg2006","article-title":"Strategies for silencing human disease using RNA interference","volume":"8","author":"Kim","year":"2007","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.drudis.2014.09.011_bib0255","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrd2310","article-title":"Interfering with disease: a progress report on siRNA-based therapeutics","volume":"6","author":"Fougerolles","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2014.09.011_bib0260","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/hmg\/11.2.175","article-title":"Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference","volume":"11","author":"Caplen","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.drudis.2014.09.011_bib0265","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.bbrc.2005.02.024","article-title":"Sleeping Beauty-mediated down-regulation of huntingtin expression by RNA interference","volume":"329","author":"Chen","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drudis.2014.09.011_bib0270","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","article-title":"RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model","volume":"102","author":"Harper","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2014.09.011_bib0275","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.neures.2005.06.021","article-title":"Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA","volume":"53","author":"Wang","year":"2005","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.drudis.2014.09.011_bib0280","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1021\/mp3003946","article-title":"Self-assembling modified beta-cyclodextrin nanoparticles as neuronal siRNA delivery vectors: focus on Huntington's disease","volume":"10","author":"Godinho","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drudis.2014.09.011_bib0285","doi-asserted-by":"crossref","first-page":"17204","DOI":"10.1073\/pnas.0708285104","article-title":"Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits","volume":"104","author":"DiFiglia","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2014.09.011_bib0290","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.bbrc.2006.02.141","article-title":"rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse","volume":"343","author":"Machida","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drudis.2014.09.011_bib0295","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ana.21569","article-title":"Sustained effects of nonallele-specific Huntingtin silencing","volume":"65","author":"Drouet","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.drudis.2014.09.011_bib0300","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1002\/jps.23672","article-title":"Non-viral nanosystems for gene and siRNA delivery to the central nervous system: formulating the solution","volume":"102","author":"O\u2019Mahony","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.drudis.2014.09.011_bib0305","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.nbd.2011.09.014","article-title":"Viral vectors for gene delivery to the central nervous system","volume":"48","author":"Lentz","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.drudis.2014.09.011_bib0310","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nrg1066","article-title":"Progress and problems with the use of viral vectors for gene therapy","volume":"4","author":"Thomas","year":"2003","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.drudis.2014.09.011_bib0315","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/jgm.378","article-title":"Antisense downregulation of mutant huntingtin in a cell model","volume":"5","author":"Hasholt","year":"2003","journal-title":"J. Gene Med."},{"key":"10.1016\/j.drudis.2014.09.011_bib0320","doi-asserted-by":"crossref","first-page":"e24308","DOI":"10.1371\/journal.pone.0024308","article-title":"Targeting several CAG expansion diseases by a single antisense oligonucleotide","volume":"6","author":"Evers","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2014.09.011_bib0325","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.biomaterials.2013.09.068","article-title":"Differential nanotoxicological and neuroinflammatory liabilities of non-viral vectors for RNA interference in the central nervous system","volume":"35","author":"Godinho","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2014.09.011_bib0330","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.addr.2007.03.010","article-title":"Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity","volume":"59","author":"Akhtar","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.drudis.2014.09.011_bib0335","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nnano.2007.223","article-title":"Immunological properties of engineered nanomaterials","volume":"2","author":"Dobrovolskaia","year":"2007","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.drudis.2014.09.011_bib0340","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1007\/s11095-008-9693-1","article-title":"Systemic delivery of DNA or siRNA mediated by linear polyethylenimine (L-PEI) does not induce an inflammatory response","volume":"25","author":"Bonnet","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.drudis.2014.09.011_bib0345","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1523\/JNEUROSCI.20-10-03705.2000","article-title":"Wild-type huntingtin protects from apoptosis upstream of caspase-3","volume":"20","author":"Rigamonti","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.drudis.2014.09.011_bib0350","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1517\/17460441.2011.555394","article-title":"Small interfering ribonucleic acid design strategies for effective targeting and gene silencing","volume":"6","author":"Malhotra","year":"2011","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.drudis.2014.09.011_bib0355","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrd3010","article-title":"Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application","volume":"9","author":"Jackson","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2014.09.011_bib0360","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/ncb1038","article-title":"Activation of the interferon system by short-interfering RNAs","volume":"5","author":"Sledz","year":"2003","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.drudis.2014.09.011_bib0365","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jmb.2005.03.013","article-title":"Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization","volume":"348","author":"Sioud","year":"2005","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.drudis.2014.09.011_bib0370","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nm1191","article-title":"Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7","volume":"11","author":"Hornung","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2014.09.011_bib0375","doi-asserted-by":"crossref","first-page":"6545","DOI":"10.4049\/jimmunol.172.11.6545","article-title":"Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3","volume":"172","author":"Karik\u00f3","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.drudis.2014.09.011_bib0380","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1261\/rna5160904","article-title":"Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs)","volume":"10","author":"Persengiev","year":"2004","journal-title":"RNA"},{"issue":"Suppl. 2","key":"10.1016\/j.drudis.2014.09.011_bib0385","doi-asserted-by":"crossref","first-page":"W124","DOI":"10.1093\/nar\/gkh442","article-title":"siDirect: highly effective, target-specific siRNA design software for mammalian RNA interference","volume":"32","author":"Naito","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.drudis.2014.09.011_bib0390","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nbt936","article-title":"Rational siRNA design for RNA interference","volume":"22","author":"Reynolds","year":"2004","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.drudis.2014.09.011_bib0395","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.4049\/jimmunol.180.5.3229","article-title":"Modifications in small interfering RNA that separate immunostimulation from RNA interference","volume":"180","author":"Eberle","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.drudis.2014.09.011_bib0400","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1261\/rna.5239604","article-title":"In vivo activity of nuclease-resistant siRNAs","volume":"10","author":"Layser","year":"2004","journal-title":"RNA"},{"key":"10.1016\/j.drudis.2014.09.011_bib0405","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature04791","article-title":"Fatality in mice due to oversaturation of cellular microRNA\/short hairpin RNA pathways","volume":"441","author":"Grimm","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2014.09.011_bib0410","first-page":"434","article-title":"In vivo knock-down of multidrug resistance transporters ABCC1 and ABCC2 by AAV-delivered shRNAs and by artificial miRNAs","volume":"7","author":"Borel","year":"2011","journal-title":"J. RNAi Gene Silencing"},{"key":"10.1016\/j.drudis.2014.09.011_bib0415","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/nbt0706-796","article-title":"RNAi in moderation","volume":"24","author":"Barik","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.drudis.2014.09.011_bib0420","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/gt.2011.10","article-title":"Lethal toxicity caused by expression of shRNA in the mouse striatum: implications for therapeutic design","volume":"18","author":"Martin","year":"2011","journal-title":"Gene Ther."},{"key":"10.1016\/j.drudis.2014.09.011_bib0425","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1261\/rna.7233305","article-title":"Overexpression of exportin 5 enhances RNA interference mediated by short hairpin RNAs and microRNAs","volume":"11","author":"Yi","year":"2005","journal-title":"RNA"},{"key":"10.1016\/j.drudis.2014.09.011_bib0430","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/mt.2008.231","article-title":"Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo","volume":"17","author":"Boudreau","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drudis.2014.09.011_bib0435","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1073\/pnas.0801775105","article-title":"Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi","volume":"105","author":"McBride","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2014.09.011_bib0440","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/brain\/awg077","article-title":"Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course","volume":"126","author":"Squitieri","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.drudis.2014.09.011_bib0445","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1523\/JNEUROSCI.6039-08.2009","article-title":"Decreased BDNF levels are a major contributor to the embryonic phenotype of huntingtin knockdown zebrafish","volume":"29","author":"Diekmann","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.drudis.2014.09.011_bib0450","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/sj.gt.3302702","article-title":"Allele-specific RNA interference for neurological disease","volume":"13","author":"Rodriguez-Lebron","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.drudis.2014.09.011_bib0455","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.nbd.2006.04.019","article-title":"Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo","volume":"23","author":"Xia","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.drudis.2014.09.011_bib0460","doi-asserted-by":"crossref","first-page":"7195","DOI":"10.1073\/pnas.1231012100","article-title":"Allele-specific silencing of dominant disease genes","volume":"100","author":"Miller","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2014.09.011_bib0465","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1089\/hum.2007.116","article-title":"Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts","volume":"19","author":"Bilsen","year":"2008","journal-title":"Human Gene Ther."},{"key":"10.1016\/j.drudis.2014.09.011_bib0470","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.expneurol.2009.03.004","article-title":"A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference","volume":"217","author":"Lombardi","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.drudis.2014.09.011_bib0475","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1371\/journal.pgen.0020140","article-title":"Designing siRNA that distinguish between genes that differ by a single nucleotide","volume":"2","author":"Schwarz","year":"2006","journal-title":"PLoS Genet."},{"key":"10.1016\/j.drudis.2014.09.011_bib0480","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1471-4159.2008.05734.x","article-title":"Allele specific silencing of mutant Huntington's disease gene","volume":"108","author":"Zhang","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.drudis.2014.09.011_bib0485","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","article-title":"Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients","volume":"19","author":"Pfister","year":"2009","journal-title":"Curr. Biol."},{"key":"10.1016\/j.drudis.2014.09.011_bib0490","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/81593","article-title":"Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice","volume":"26","author":"Dragatsis","year":"2000","journal-title":"Nat. Genet."},{"key":"10.1016\/j.drudis.2014.09.011_bib0495","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.7618107","article-title":"Inactivation of the mouse Huntington's disease gene homolog Hdh","volume":"269","author":"Duyao","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.drudis.2014.09.011_bib0500","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/mt.2009.17","article-title":"Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice","volume":"17","author":"Boudreau","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drudis.2014.09.011_bib0505","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/mt.2011.219","article-title":"Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease","volume":"19","author":"McBride","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drudis.2014.09.011_bib0510","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/brain\/awr333","article-title":"Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum","volume":"135","author":"Grondin","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.drudis.2014.09.011_bib0515","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.expneurol.2011.11.020","article-title":"Widespread suppression of huntingtin with convection-enhanced delivery of siRNA","volume":"233","author":"Stiles","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.drudis.2014.09.011_bib0520","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/mt.2010.293","article-title":"Suppression and replacement gene therapy for autosomal dominant disease in a murine model of dominant retinitis pigmentosa","volume":"19","author":"Millington-Ward","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drudis.2014.09.011_bib0525","doi-asserted-by":"crossref","first-page":"14258","DOI":"10.1073\/pnas.1109522108","article-title":"Combination therapy utilizing shRNA knockdown and an optimized resistant transgene for rescue of diseases caused by misfolded proteins","volume":"108","author":"Li","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2014.09.011_bib0530","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1089\/hum.2010.054","article-title":"In vivo application of an RNAi strategy for the selective suppression of a mutant allele","volume":"22","author":"Kubodera","year":"2011","journal-title":"Human Gene Ther."},{"key":"10.1016\/j.drudis.2014.09.011_bib0535","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1089\/oli.2005.15.298","article-title":"New RNAi strategy for selective suppression of a mutant allele in polyglutamine disease","volume":"15","author":"Kubodera","year":"2005","journal-title":"Oligonucleotides"},{"key":"10.1016\/j.drudis.2014.09.011_bib0540","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","article-title":"ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering","volume":"31","author":"Gaj","year":"2013","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.drudis.2014.09.011_bib0545","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/nature03556","article-title":"Highly efficient endogenous human gene correction using designed zinc-finger nucleases","volume":"435","author":"Urnov","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2014.09.011_bib0550","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature10177","article-title":"In vivo genome editing restores haemostasis in a mouse model of haemophilia","volume":"475","author":"Li","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2014.09.011_bib0555","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1182\/blood-2011-02-335554","article-title":"Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease","volume":"118","author":"Zou","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2014.09.011_bib0560","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cell.2011.06.019","article-title":"Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations","volume":"146","author":"Soldner","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2014.09.011_bib0565","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/emmm.201000119","article-title":"Zinc-finger-based transcriptional repression of rhodopsin in a model of dominant retinitis pigmentosa","volume":"3","author":"Mussolino","year":"2011","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.drudis.2014.09.011_bib0570","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nbt.1663","article-title":"Human hematopoietic stem\/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo","volume":"28","author":"Holt","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.drudis.2014.09.011_bib0575","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV","volume":"370","author":"Tebas","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2014.09.011_bib0580","doi-asserted-by":"crossref","first-page":"E3136","DOI":"10.1073\/pnas.1206506109","article-title":"Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6\/2 mice","volume":"109","author":"Garriga-Canut","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2014.09.011_bib0585","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/157341311794480336","article-title":"Targeted drug delivery across blood\u2013brain-barrier using cell penetrating peptides tagged nanoparticles","volume":"7","author":"Malhotra","year":"2011","journal-title":"Curr. Nanosci."},{"key":"10.1016\/j.drudis.2014.09.011_bib0590","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1007\/s11095-012-0945-8","article-title":"In vitro investigations of the efficacy of cyclodextrin-siRNA complexes modified with lipid-PEG-Octaarginine: towards a formulation strategy for non-viral neuronal siRNA delivery","volume":"30","author":"O\u2019Mahony","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.drudis.2014.09.011_bib0595","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.biomaterials.2011.03.047","article-title":"A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA","volume":"32","author":"Hwang do","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2014.09.011_bib0600","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1016\/j.biomaterials.2011.03.031","article-title":"Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides","volume":"32","author":"Li","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2014.09.011_bib0605","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jconrel.2009.11.004","article-title":"Tf-lipoplex-mediated c-Jun silencing improves neuronal survival following excitotoxic damage in vivo","volume":"142","author":"Cardoso","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drudis.2014.09.011_bib0610","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.biomaterials.2010.09.024","article-title":"Lactoferrin-conjugated superparamagnetic iron oxide nanoparticles as a specific MRI contrast agent for detection of brain glioma in vivo","volume":"32","author":"Xie","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2014.09.011_bib0615","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1016\/j.biomaterials.2012.01.025","article-title":"The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2","volume":"33","author":"Ren","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2014.09.011_bib0620","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/ilar.48.4.356","article-title":"Animal models of Huntington's disease","volume":"48","author":"Ramaswamy","year":"2007","journal-title":"ILAR J."},{"key":"10.1016\/j.drudis.2014.09.011_bib0625","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1523\/JNEUROSCI.11-06-01649.1991","article-title":"Chronic quinolinic acid lesions in rats closely resemble Huntington's disease","volume":"11","author":"Beal","year":"1991","journal-title":"J. Neurosci."},{"key":"10.1016\/j.drudis.2014.09.011_bib0630","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/263244a0","article-title":"Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea","volume":"263","author":"Coyle","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2014.09.011_bib0635","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1523\/JNEUROSCI.13-10-04181.1993","article-title":"Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid","volume":"13","author":"Beal","year":"1993","journal-title":"J. Neurosci."},{"key":"10.1016\/j.drudis.2014.09.011_bib0640","series-title":"Neurobiology of Huntington's Disease: Applications to Drug Discovery","article-title":"Mouse models for validating preclinical candidates for Huntington's disease","author":"Yang","year":"2011"},{"key":"10.1016\/j.drudis.2014.09.011_bib0645","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2014.09.011_bib0650","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/hmg\/8.3.397","article-title":"Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant n-terminal fragment of huntingtin","volume":"8","author":"Schilling","year":"1999","journal-title":"Human Mol. Genet."},{"key":"10.1016\/j.drudis.2014.09.011_bib0655","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0896-6273(00)80764-3","article-title":"A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration","volume":"23","author":"Hodgson","year":"1999","journal-title":"Neuron"},{"key":"10.1016\/j.drudis.2014.09.011_bib0660","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","article-title":"Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease","volume":"12","author":"Slow","year":"2003","journal-title":"Human Mol. Genet."},{"key":"10.1016\/j.drudis.2014.09.011_bib0665","doi-asserted-by":"crossref","first-page":"15426","DOI":"10.1523\/JNEUROSCI.1148-12.2012","article-title":"A novel BACHD transgenic rat exhibits characteristic neuropathological features of Huntington disease","volume":"32","author":"Yu-Taeger","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.drudis.2014.09.011_bib0670","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/hmg\/9.4.503","article-title":"Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice","volume":"9","author":"Wheeler","year":"2000","journal-title":"Human Mol. Genet."},{"key":"10.1016\/j.drudis.2014.09.011_bib0675","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/cne.10776","article-title":"Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats","volume":"465","author":"Menalled","year":"2003","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.drudis.2014.09.011_bib0680","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/hmg\/10.2.137","article-title":"Neurological abnormalities in a knock-in mouse model of Huntington's disease","volume":"10","author":"Lin","year":"2001","journal-title":"Human Mol. Genet."},{"key":"10.1016\/j.drudis.2014.09.011_bib0685","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/nrn1806","article-title":"Normal huntingtin function: an alternative approach to Huntington's disease","volume":"6","author":"Cattaneo","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.drudis.2014.09.011_bib0705","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1039\/b307062j","article-title":"Synthetic, self-assembly ABCD nanoparticles; a structural paradigm for viable synthetic non-viral vectors","volume":"34","author":"Kostarelos","year":"2005","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.drudis.2014.09.011_bib0710","first-page":"1143","article-title":"Therapeutic targeting in the silent era: advances in non-viral siRNA delivery","volume":"6","author":"Guo","year":"2010","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.drudis.2014.09.011_bib0715","doi-asserted-by":"crossref","first-page":"11926","DOI":"10.1073\/pnas.182272699","article-title":"RNAi functions in cultured mammalian neurons","volume":"99","author":"Krichevsky","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2014.09.011_bib0690","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1089\/hum.2006.160","article-title":"High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo","volume":"18","author":"Huang","year":"2007","journal-title":"Human Gene Ther."},{"key":"10.1016\/j.drudis.2014.09.011_bib0695","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/mt.2008.50","article-title":"AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease","volume":"16","author":"Franich","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drudis.2014.09.011_bib0700","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jconrel.2012.08.012","article-title":"Focused ultrasound for targeted delivery of siRNA and efficient knockdown of Htt expression","volume":"163","author":"Burgess","year":"2012","journal-title":"J. Control. Release"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644614003778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644614003778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:21:02Z","timestamp":1761222062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644614003778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":143,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S1359644614003778"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2014.09.011","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delivering a disease-modifying treatment for Huntington's disease","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2014.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}